![]() Usage of Nucleo CMP Forte in the combined treatment of patients has more expressed positive influence on problems with walking. We used non-parametric test χ 2 to evaluate efficacy of therapy. Nombre Genrico: Citidn-5’ Monofosfato / Citidn-5’ Trifosfato. Nucleo CMP forte is a medication used to treat paraparesis, partial paralysis in both legs, characterized by progressive weakness and spasms in the legs. La investigación, iniciada en 2004, se centraba en un principio en estudiar el efecto del fármaco en la regeneración de las células. Patients filled questionnaire of life quality EQ-5D-3L (Ukraine 2004, EuroQol) on the first and tenth day of treatment. Ncleo CMP Forte es un medicamento compuesto por Citidn-5’ monofosfato y Citidn-5’ trifosfato, dos compuestos que funcionan para proteger el sistema nervioso y regenerar la vaina de mielina, una capa protectora que poseen los nervios. La compañía farmacéutica Ferrer International ha concedido una nueva subvención a la UIC para avanzar en el estudio del fármaco Nucleo CMP Forte. ![]() They were compared into two groups: A 30 patients received standard treatment, B 29 diabetics additionally were taken Nucleo CMP Forte (1 capsule three times a day). Methods: It was examined 59 (41≧9 years old) patients with type 2 DM and DPNP. ![]() The aim: To evaluate the efficacy of Nucleo CMP Forte (Cytidine 5- disodium monophosphate and Uridine 5- trisodium triphosphate) in the combined treatment of patients with DPNP. ![]() New medications in DPNP have to be studied. Introduction: The protocols of medical care of diabetic peripheral neuropathy (DPNP) are developed but positive effect cannot be achieved in all patients. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |